{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:42:13Z","timestamp":1773661333585,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003977","name":"The Israel Science Foundation","doi-asserted-by":"crossref","award":["ISF494\/04-08"],"award-info":[{"award-number":["ISF494\/04-08"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Israel Cancer Association (ICA","award":["20052008"],"award-info":[{"award-number":["20052008"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.bcp.2013.06.004","type":"journal-article","created":{"date-parts":[[2013,6,14]],"date-time":"2013-06-14T14:02:20Z","timestamp":1371218540000},"page":"584-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway"],"prefix":"10.1016","volume":"86","author":[{"given":"Hanan","family":"Galski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Oved-Gelber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masha","family":"Simanovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Lazarovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Gottesman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2013.06.004_bib0005","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.2174\/138161211796904803","article-title":"Mitochondrial drug targets in cell death and cancer","volume":"17","author":"Ferr\u00edn","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.bcp.2013.06.004_bib0010","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1038\/onc.2010.221","article-title":"New insights into apoptosis signaling by Apo2L\/TRAIL","volume":"29","author":"Gonzalvez","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2013.06.004_bib0015","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cytogfr.2004.03.011","article-title":"Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system","volume":"15","author":"Eissner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.bcp.2013.06.004_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bcp.2013.06.004_bib0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.immuni.2009.01.001","article-title":"The many roles of FAS receptor signaling in the immune system","volume":"30","author":"Strasser","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2013.06.004_bib0030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2567.2009.03058.x","article-title":"Following TRAIL's path in the immune system","volume":"127","author":"Falschlehner","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.bcp.2013.06.004_bib0035","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol Immunol"},{"key":"10.1016\/j.bcp.2013.06.004_bib0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejphar.2009.06.066","article-title":"TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies","volume":"625","author":"Holoch","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2013.06.004_bib0045","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14728222.2010.519701","article-title":"TRAIL receptor signaling and therapeutics","volume":"14","author":"Abdulghani","year":"2010","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bcp.2013.06.004_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2010.460","article-title":"Towards novel paradigms for cancer therapy","volume":"30","author":"Pavet","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2013.06.004_bib0055","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-011-1008-4","article-title":"Targeting the extrinsic apoptosis signaling pathway for cancer therapy","volume":"60","author":"Sayers","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.bcp.2013.06.004_bib0060","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2013.06.004_bib0065","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbapap.2009.02.014","article-title":"A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function","volume":"1794","author":"Fung","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2013.06.004_bib0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/jnci\/81.2.116","article-title":"Expression of a multidrug resistance gene in human cancer","volume":"81","author":"Goldstein","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bcp.2013.06.004_bib0075","first-page":"57","article-title":"Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia","volume":"9","author":"Galski","year":"1989","journal-title":"Mol Cell Biol"},{"issue":"Suppl. 2","key":"10.1016\/j.bcp.2013.06.004_bib0080","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF03165119","article-title":"Biology and modulation of multidrug resistance (MDR) in hematological malignancies","volume":"76","author":"Hirose","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bcp.2013.06.004_bib0085","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/0959-8049(96)00047-0","article-title":"Experimental reversal of P-glycoprotein mediated multidrug resistance by pharmacological chemosensitizers","volume":"32","author":"Ford","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bcp.2013.06.004_bib0090","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","article-title":"Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein","volume":"10","author":"Thomas","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.bcp.2013.06.004_bib0095","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.leukres.2006.02.016","article-title":"In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies","volume":"30","author":"Galski","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.bcp.2013.06.004_bib0100","first-page":"3084","article-title":"P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential","volume":"63","author":"Alem\u00e1n","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bcp.2013.06.004_bib0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.leukres.2004.09.001","article-title":"Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1","volume":"29","author":"Findling-Kagan","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.bcp.2013.06.004_bib0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M","article-title":"A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture","volume":"24","author":"van Engeland","year":"1996","journal-title":"Cytometry"},{"key":"10.1016\/j.bcp.2013.06.004_bib0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jss.2006.07.034","article-title":"Screening and detection of apoptosis","volume":"139","author":"Huerta","year":"2007","journal-title":"J Surg Res"},{"key":"10.1016\/j.bcp.2013.06.004_bib0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/jpet.106.110155","article-title":"Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of inhibitors and the UIC2 monoclonal antibody","volume":"320","author":"Goda","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2013.06.004_bib0125","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1046\/j.1432-1327.2001.02122.x","article-title":"P-glycoprotein conformational changes detected by antibody competition","volume":"268","author":"Nagy","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.bcp.2013.06.004_bib0130","first-page":"133","article-title":"Expression of the IAPs in multidrug resistant tumor cells","volume":"11","author":"Notarbartolo","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bcp.2013.06.004_bib0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s002800050682","article-title":"Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines","volume":"40","author":"Hoki","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bcp.2013.06.004_bib0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bcp.2006.04.024","article-title":"P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5","volume":"72","author":"Park","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2013.06.004_bib0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2008.02.001","article-title":"TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them","volume":"2","author":"Thorburn","year":"2008","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.bcp.2013.06.004_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428190009060314","article-title":"A role for P-glycoprotein in regulating cell death","volume":"38","author":"Johnstone","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bcp.2013.06.004_bib0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/157488709787047530","article-title":"TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges","volume":"4","author":"Bellail","year":"2009","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.bcp.2013.06.004_bib0160","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1080\/10428190290026277","article-title":"P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype","volume":"43","author":"Pallis","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bcp.2013.06.004_bib0165","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.cdd.4401440","article-title":"Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux","volume":"11","author":"Tainton","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bcp.2013.06.004_bib0170","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/138920008783571756","article-title":"Genuine functions of P-glycoprotein (ABCB1)","volume":"9","author":"Mizutani","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.bcp.2013.06.004_bib0175","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cyto.a.20081","article-title":"Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein","volume":"61","author":"Bacso","year":"2004","journal-title":"Cytometry A"},{"key":"10.1016\/j.bcp.2013.06.004_bib0180","doi-asserted-by":"crossref","first-page":"11641","DOI":"10.1074\/jbc.M411781200","article-title":"Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy","volume":"280","author":"Gajate","year":"2005","journal-title":"J Biol Chem"}],"updated-by":[{"DOI":"10.1016\/j.bcp.2014.08.020","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000}}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213003596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295213003596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:57:26Z","timestamp":1757768246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295213003596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0006295213003596"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2013.06.004","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.bcp.2014.08.020","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2013.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}